natgillin/translations-raw huggingface dataset:
In a study where the dosage form of three 1 mg blisters was compared with one 3 mg blister, Cmax and AUC of inhaling three 1 mg blisters were approximately 30% and 40% greater, respectively, than that of inhaling from one 3 mg blister, indicating that three 1 mg blisters are not interchangeable with one 3 mg blister (see sections 2, 4.2 and 4.4). 
V študiji, v kateri so obliko odmerjanja s tremi 1-mg pretisnimi omoti primerjali z enim 3-mg pretisnim omotom, sta bili Cmax in AUC po inhalaciji treh 1-mg pretisnih omotov približno za 30 % in 40 % večji kot po inhalaciji iz enega 3-mg pretisnega omota, kar kaže na to, da trije 1-mg pretisni omoti niso zamenljivi z enim 3mg pretisnim omotom (glejte poglavja 2, 4.2 in 4.4).
- If you have further questions, please ask your doctor, diabetes nurse or pharmacist. 
- Če imate dodatna vprašanja, se posvetujte z zdravnikom, medicinsko sestro za diabetike ali s
If any of these side effects get serious or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. 
Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
6.6 Special precautions for disposal and other handling EXUBERA unit dose blisters must only be used with the insulin inhaler. 
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom Enoodmerni pretisni omoti zdravila EXUBERA se smejo uporabljati samo z insulinskim inhalatorjem.
A unit dose blister is the individual container in which the insulin powder is packaged and will be called a blister in the rest of this leaflet. 
Enoodmerni pretisni omot je posamični vsebnik, v katerem je pakiran insulinski prašek, in ga bomo v nadaljevanju tega navodila imenovali pretisni omot.
A number of substances affect glucose metabolism and may require dose adjustment of insulin. 
Številne snovi vplivajo na presnovo glukoze, tako da utegne zaradi njih biti potrebna prilagoditev odmerka insulina.
In contrast, exposure to other people's cigarette smoke may decrease the amount of insulin your body 
V nasprotju s tem lahko izpostavljenost dimu cigaret, ki jih kadijo drugi, zmanjša količino insulina, ki
• If you are allergic to insulin, the active ingredient contained in EXUBERA or any of the other ingredients of EXUBERA. 
- če ste preobčutljivi za (alergični na) insulin, zdravilno učinkovino v zdravilu EXUBERA, ali katerokoli sestavino zdravila EXUBERA.
Inadequate dosage or discontinuation of treatment especially in insulin-dependant diabetics, may lead to hyperglycaemia and diabetic ketoacidosis; conditions which are potentially lethal. 
Nezadostno odmerjanje ali prekinitev zdravljenja, posebno pri diabetikih, odvisnih od insulina, lahko povzroči hiperglikemijo in diabetično ketoacidozo, ki lahko povzročita smrt.
When EXUBERA was administered to healthy volunteers following 2-hours of passive exposure to cigarette smoke in a controlled experimental setting, insulin AUC and Cmax were reduced by approximately 17 and 30%, respectively (see section 4.5). 
Ko so zdravilo EXUBERA dajali zdravim prostovoljcem po dveurni pasivni izpostavljenosti cigaretnemu dimu v kontroliranih eksperimentalnih razmerah, sta se AUC in Cmax insulina zmanjšala za približno 17 oziroma 30 % (glejte poglavje 4.5).
INFORMATION IN BRAILLE EXUBERA 1 mg 
INFORMACIJE V BRAILLOVI PISAVI Exubera 1 mg
For any information about this medicine, please contact the local EXUBERA Customer Care Centre. 
Za kakršnekoli informacije o tem zdravilu se obrnite na Center za svetovanje o zdravilu EXUBERA v
The Insulin Release Unit (IRU) should be replaced once every 2 weeks. 
Nastavek za sproščanje (Insulin release unit - IRU) je treba zamenjati enkrat na 2 tedna.
The tray is sealed in a plastic foil pouch with a desiccant, which keeps the medicine dry and should not be eaten. 
Podstavek je zavarjen v vrečki iz plastične folije in ima priloženo sušilno sredstvo; slednje ohranja zdravilo suho, in ga ne smete zaužiti.
Change from Baseline in FEV1 (L) ( Mean +/- SD) 
Sprememba FEV1 (l) od izhodišča ( povprečje +/- SD)
- you have had diabetes for a long time - due to diabetes, you suffer from a certain type of nervous disease (autonomic neuropathy), - you have recently suffered hypoglycaemia (e.g. the day before) or if it develops slowly, - you have almost normal or, at least, greatly improved blood sugar levels, - you are taking or have taken certain other medicines (see section 2, “Taking other medicines”). 
- imate sladkorno bolezen že dolgo časa, - imate zaradi sladkorne bolezni določeno vrsto bolezni živčevja (avtonomno nevropatijo), - ste pred nedavnim (npr. en dan prej) imeli hipoglikemijo ali če se le-ta razvija počasi, - imate skoraj normalne ali vsaj močno izboljšane koncentracije krvnega sladkorja, - jemljete ali ste jemali nekatera druga zdravila (glejte poglavje 2 “Jemanje drugih zdravil”).
In non-diabetic subjects with mild to moderate asthma, AUC and Cmax for inhaled human insulin in the absence of treatment with a bronchodilator was slightly less than in subjects without asthma. 
Pri nediabetičnih preiskovancih z blago do zmerno astmo sta bili AUC in Cmax humanega insulina za inhaliranje v odsotnosti zdravljenja z bronhodilatatorjem nekoliko manjši kot pri preiskovancih brez
In subjects with diabetes and in subjects without diabetes, no apparent differences in absorption of inhaled human insulin were observed between men and women. 
Pri osebah s sladkorno boleznijo in osebah brez nje niso opazili jasnih razlik med moškimi in ženskami glede absorpcije humanega insulina za inhaliranje.
No further information is available for the remaining 3 subjects who discontinued. 
Za ostale tri bolnike, ki so prenehali sodelovati v študiji, nadaljnih informacij ni.
All patients initiated on EXUBERA should have a baseline lung function examination (e.g. spirometry to measure FEV1). 
Vsi bolniki, ki začenjajo uporabljati EXUBERO, morajo opraviti izhodiščno preiskavo pljučne funkcije (npr. spirometrijo za določitev FEV1).
Of these patients, 5 exhibited a significant improvement in FEV1 following discontinuation of therapy and one subject did not decrease further from the end of study value. 
Petim izmed teh se je funkcija FEV1 po prekinitvi terapije pomembno izboljšala, enemu bolniku pa se v primerjavi z vrednostjo ob prekinitvi sodelovanja v študiji ni več zmanjševala.
INFORMATION IN BRAILLE EXUBERA 3 mg 
INFORMACIJE V BRAILLOVI PISAVI Exubera 3 mg
Patients must not smoke during therapy with EXUBERA and must have stopped smoking at least 6 months prior to starting EXUBERA therapy. 
Med zdravljenjem z zdravilom EXUBERA bolniki ne smejo kaditi, v poštev za zdravljenje s tem zdavilom pridejo samo bolniki, ki so prenehali kaditi vsaj 6 mesecev pred začetkom zdravljenja.
One subject in the EXUBERA and one in the comparator group discontinued treatment due to chest pain. 
En preiskovanec v skupini z zdravilom EXUBERA, in eden v skupini s primerjalnim zdravilom sta prekinila zdravljenje zaradi bolečine v prsih.
If at 6 months a decline of 15-20% or > 500ml from baseline lung function is observed, spirometry should be repeated after 3 months. 
Če je po 6 mesecih opazno zmanjšanje za 1520 % ali 500 ml od izhodiščnega izvida, je treba spirometrijo ponoviti čez 3 mesece.
Insulin antibody levels were higher in patients with type 1 diabetes compared to type 2 diabetes and plateaued within 6-12 months of exposure in both groups. 
Koncentracije insulinskih protiteles so bile višje pri bolnikih z diabetesom tipa 1 kot pri tistih z diabetesom tipa 2 in so pri obeh skupinah dosegle plato po 6-12 mesecih izpostavljenosti.
Hypoglycaemia, in general the most frequent undesirable effect of insulin therapy including EXUBERA and many oral antidiabetic agents, may occur if the insulin dose is too high in relation to the insulin requirement. 
Hipoglikemija, ki je na splošno najpogostejši neželeni učinek zdravljenja z insulinom in tudi zdravljenja z zdravilom EXUBERA in številnimi peroralnimi antidiabetiki, se lahko pojavi, če je odmerek insulina prevelik glede na potrebo po njem.
Carry some information with you to show you are diabetic. 
Pri sebi imejte nekaj, iz česar bo razvidno, da imate sladkorno bolezen.
Human insulin lowers blood glucose and promotes anabolic effects as well as decreasing catabolic effects, increases the transport of glucose into cells as well as the formation of glycogen in the muscles and the liver, and improves pyruvate utilisation. 
Humani insulin znižuje glukozo v krvi in pospešuje anabolne učinke ter zmanjšuje katabolne učinke, zvečuje transport glukoze v celice in nastajanje glikogena v mišicah in jetrih ter izboljšuje izrabo piruvata.
Discontinuation of EXUBERA therapy after 2 years resulted in resolution of treatment group differences within 6 weeks (see sections 4.4 and 5.1). 
Prekinitev zdravljenja z zdravilom EXUBERA po 2 letih je povzročila izginotje razlik med skupinama z različnima zdraviloma v 6 tednih (glejte poglavji 4.4 in 5.1).
What EXUBERA looks like and contents of the pack 
Izgled zdravila EXUBERA in vsebina pakiranja
- The active substance is insulin human. 
- Zdravilna učinkovina je humani insulin.
EXUBERA should be taken within 10 minutes before the start of a meal. 
Zdravilo EXUBERA vzemite največ 10 minut pred začetkom obroka.
• If you have poorly controlled , unstable, or severe asthma. 
- če imate slabo urejeno, nestabilno ali hudo astmo.
Omission of a meal or unplanned, strenuous physical exercise may lead to hypoglycaemia. 
Opustitev obroka ali nenačrtovana naporna telesna aktivnost lahko povzroči hipoglikemijo.
The use of a bronchodilator (reliever inhaler) for asthma or other airway conditions may cause a more pronounced fall in blood sugar in response to inhaled insulin (see section 2 “Do not take EXUBERA” and section 2 “Take special care with EXUBERA”). 
Uporaba bronhodilatatorja (inhalator za olajšanje) za astmo ali druge bolezni dihal lahko povzroči izrazitejše znižanje krvnega sladkorja v odziv na inhalirani insulin (glejte poglavje 2 “Ne jemljite zdravila EXUBERA“ in “Bodite posebno pozorni pri uporabi zdravila EXUBERA”).
This may include a mix of 1 mg (green coloured) and 3 mg (blue coloured) blisters. 
Ta lahko obsega mešanico 1-mg (zelenih) in 3-mg (modrih) pretisnih omotov.
If you are under 18 years of age, please speak to your doctor, as use of EXUBERA is not recommended for patients under 18 years of age. 
Če ste mlajši od 18 let, se pogovorite z zdravnikom, ker uporabe zdravila EXUBERA pri bolnikih,
Dose adjustment may be required based on the meal size and nutrient composition, time of day (higher insulin requirements in the morning), pre-meal blood glucose concentration, recent or 
Prilagoditev odmerka utegne biti potrebna na podlagi velikosti obroka in hranilni sestavi, dnevnega časa (večje potrebe po insulinu zjutraj), koncentracije glukoze v krvi pred obrokom, nedavne ali
It is important that you take the number of 1 mg and 3 mg blisters that your doctor recommends in the combination that he or she recommends. 
Pomembno je, da vzamete toliko 1-mg in 3-mg pretisnih omotov v takšni kombinaciji, kot vam je priporočil zdravnik.
Hold the insulin inhaler upright with the blue button facing towards you. 
Primite insulinski inhalator in ga držite navpično, modri gumb naj bo obrnjen proti vam.
Administration of EXUBERA 10 minutes prior to administration of salbutamol did not affect the bronchodilatory response to salbutamol in non-diabetic subjects with mild-moderate asthma. 
Dajanje zdravila EXUBERA 10 minut pred dajanjem salbutamola ni vplivalo na bronhodilatacijski odziv na salbutamol pri nediabetičnih osebah z blago do zmerno astmo.
Oedema and refraction abnormalities of the eye 
Edem in refrakcijske očesne nenormalnosti
Long-term safety of inhaled human insulin has not been established in paediatric patients with diabetes and its use is therefore not recommended in patients under 18 years of age (see section 5.2). 
Pri pediatričnih bolnikih s sladkorno boleznijo niso dokazali dolgoročne varnosti humanega insulina za inhaliranje, zato ne priporočamo njegove uporabe pri bolnikih, mlajših od 18 let (glejte poglavje
It also promotes the uptake of amino acids into cells and promotes protein synthesis and enhances the uptake of potassium into cells. 
Pospešuje tudi privzem aminokislin v celice in pospešuje sintezo beljakovin in zvečuje privzem kalija v celice.
Insulin treatment may also cause temporary build-up of water in the body with swelling in the calves and ankles. 
Zdravljenje z insulinom lahko povzroči tudi začasno kopičenje vode v telesu z otekanjem meč in
The efficacy and safety of inhaled human insulin in patients with baseline FEV1 < 70% predicted have not been established and the use of inhaled human insulin in this population is not recommended A follow-up lung function measurement is recommended after the first 6 months of therapy. 
Učinkovitost in varnost humanega insulina za inhaliranje pri bolnikih z izhodiščnim FEV1 < 70 % nista bili določeni in uporaba humanega insulina za inhaliranje pri tej populaciji ni priporočljiva.Po prvih 6 mesecih zdravljenja je priporočljiva ponovna ocena pljučne funkcije.
In EXUBERA treated subjects 0.4% discontinued treatment due to dyspnoea. 
Od oseb, zdravljenih z zdravilom EXUBERA, jih je 0,4 % prekinilo zdravljenje zaradi dispneje.
Active smoking greatly enhances whereas passive exposure to tobacco smoke in non-smokers decreases the rate and extent of absorption of EXUBERA (see sections 4.3 and 5.2). 
Aktivno kajenje močno poveča hitrost in obseg absorpcije EXUBERE, pasivna izpostavljenost nekadilcev tobačnemu dimu pa ju zmanjša (glejte poglavji 4.3 in 5.2).
They may include cold sweats, cool pale skin, fatigue, nervousness or tremor, anxiousness, unusual tiredness or weakness, confusion, difficulty in concentration, drowsiness, excessive hunger, vision changes, headache, nausea and palpitation. 
Lahko obsegajo hladen znoj, hladno bledo kožo, utrujenost, živčnost ali tremor, tesnobo, nenavadno utrujenost ali šibkost, zmedenost, oteženo koncentriranje, zaspanost, čezmerno lakoto, spremembe vida, glavobol, navzejo in palpitacije.
The following symptoms indicate a low sugar level in the brain: headaches, intense hunger, nausea, vomiting, tiredness, sleepiness, sleep disturbances, restlessness, aggressive behaviour, lapses in concentration, impaired reactions, depression, confusion, speech disturbances (sometimes total loss of speech), visual disorders, trembling, paralysis, tingling sensations (paraesthesia), numbness and tingling sensations in the area of the mouth, dizziness, loss of self-control, inability to look after yourself, convulsions, loss of consciousness. 
Naslednji simptomi kažejo na nizko koncentracijo sladkorja v možganih: glavoboli, močna lakota, slabost s siljenjem na bruhanje, bruhanje, utrujenost, zaspanost, motnje spanja, nemir, agresivno vedenje, motnje koncentracije, upočasnjene reakcije, depresija, zmedenost, motnja govora (včasih popolna izguba govora), motnje vida, tresenje, ohromelost, mravljinčenje (parestezije), odrevenelost in mravljinčenje v predelu ust, vrtoglavica, izguba samoobvladovanja, nezmožnost skrbeti zase, konvulzije (napadi krčev), izguba zavesti.
The contents of the blisters should be breathed in through your mouth into your lungs using the insulin inhaler. 
Vsebino pretisnega omota morate vdihniti skozi usta v pljuča s pomočjo insulinskega inhalatorja.
While cleaning the top of the base be careful not to get any water into the IRU. 
Pri čiščenju zgornjega dela podnožja pazite, da v nastavek za sproščanje insulina ne bo prišla voda.
Hypoglycaemia (low blood sugar levels) are also more likely to occur if: - you have just begun insulin treatment or changed to another insulin preparation, - your blood sugar levels are almost normal or are unstable, - you suffer from severe kidney or liver disease, or some other disease such as hypothyroidism. 
Hipoglikemija (nizka koncentracija krvnega sladkorja) se bo verjetneje pojavila tudi, če: - ste se pravkar začeli zdraviti z insulinom ali prešli na drug insulinski pripravek, - so koncentracije vašega krvnega sladkorja skoraj normalne ali so nestabilne, - imate težjo bolezen ledvic ali jeter ali kakšno drugo bolezen, na primer hipotiroidizem.
Inhaled insulin frequently induces insulin antibodies, the risk of which to the foetus is not known. 
Inhalirani insulin pogosto povzroči nastanek insulinskih protiteles, za katera ni znano, ali predstavljajo nevarnost za plod.
If you are ill or have a major injury, then your blood sugar may increase (hyperglycaemia) or if you are not eating enough your blood sugar may become too low (hypoglycaemia). 
Če ste bolni ali se huje poškodujete, se utegne vaš krvni sladkor zvišati (hiperglikemija), če ne jeste dovolj, pa se lahko zniža (hipoglikemija).
Controlled clinical trials in type 1 or type 2 diabetes have shown that EXUBERA achieves and maintains effective glycaemic control comparable to subcutaneously administered fast-acting human insulin. 
Kontrolirana klinična preskušanja pri diabetesu tipa 1 ali tipa 2 so pokazala, da EXUBERA doseže in vzdržuje učinkovito glikemično kontrolo, ki je primerljiva s tisto pri subkutano apliciranem hitrodelujočem humanem insulinu.
In a smaller group (n=36) of mixed type 1 and 2 subjects treated with EXUBERA for > 36 months, cessation of therapy resulted in a mean FEV1 increase of 0.036L over the subsequent 6 months. 
V manjši mešani skupini (n=36) bolnikov s tipom 1 in tipom 2, zdravljenih z zdravilom EXUBERA > 36 mesecev dolgo, je prekinitev zdravljenja povzročila povprečno zvečanje FEV1 za 0,036 L v naslednjih 6 mesecih.
FEV1 decline 
Zmanjšanje FEV1
EXUBERA is indicated for the treatment of adult patients with type 2 diabetes mellitus not adequately controlled with oral antidiabetic agents and requiring insulin therapy. 
EXUBERA je indicirana za zdravljenje odraslih bolnikov z diabetesom mellitusom tipa 2, ki ni ustrezno urejen s peroralnimi antidiabetiki in potrebujejo insulinsko terapijo.
A range of different chest symptoms were reported as treatment-related adverse reactions and were referred to as non-specific chest pain. 
O različnih torakalnih simptomih so poročali kot o neželenih učinkih, povezanih z zdravilom, in jih imenovali nespecifična bolečina v prsih.
During intercurrent respiratory illness close monitoring of blood glucose concentrations and dose adjustment may be required on an individual basis (see section 4.2). 
Med interkurentnim obolenjem dihal utegne biti pri posameznih bolnikih potrebno natančno spremljanje koncentracij glukoze v krvi in prilagajanje odmerka (glejte poglavje 4.2).
EXUBERA (inhaled human insulin) is a fast-acting human insulin for use in type 1 or type 2 diabetes. 
EXUBERA (humani insulin za inhaliranje) je hitrodelujoč insulin za uporabo pri sladkorni bolezni tipa 1 ali tipa 2.
Please see the “Instructions for Use” at the end of the package leaflet for advice on how to use your insulin inhaler, and how to care for it. 
Glejte tudi “Navodilo za uporabo insulinskega inhalatorja” na koncu tega navodila, kjer boste našli nasvete o tem, kako uporabljajte svoj insulinski inhalator in kako skrbite zanj.
In patients with a confirmed (i.e. at least two consecutive tests, 3 to 4 weeks apart) FEV1 decline of > 20% from baseline, EXUBERA therapy should be discontinued and the patient monitored as clinically indicated. 
Pri bolnikih, ki se jim FEV1 potrjeno (npr. na vsaj dveh zaporednih testiranjih, 3 do 4 tedne ločeno) zmanjša za > 20 % v primerjavi z izhodiščnim FEV1, je treba zdravljenje z EXUBERO prekiniti in bolnika nadzirati, kot je klinično indicirano.
Do not take EXUBERA 
Ne jemljite zdravila EXUBERA
The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market. 
Imetnik dovoljenja za promet mora pred prihodom zdravila na trg zagotoviti vzpostavitev in delovanje sistema farmakovigilance.
Store the insulin inhaler in a dry place at room temperature. 
Insulinski inhalator shranjujte na suhem mestu pri sobni temperaturi.
In clinical trials of Exubera, there have been 6 newly diagnosed cases of primary lung malignancies among Exubera-treated patients, and 1 newly diagnosed case among comparator treated patients. 
V kliničnih preskušanjih zdravila EXUBERA so zabeležili 6 novoodkritih primerov primarnega malignoma pljuč med bolniki, zdravljenimi z zdravilom EXUBERA, in 1 novoodkrit primer med bolniki, zdravljenimi s primerjalnim zdravilom.
The cough tended to occur within seconds to minutes after insulin inhalation and was predominantly mild in severity. 
Kašelj se je navadno pojavljal v nekaj sekundah do nekaj minutah po inhalaciji insulina in je bil, kar se izraženosti tiče, pretežno blag.
Adjustments in drug dosage, meal patterns, or exercise may be needed. 
Potrebno utegne biti prilagajanje odmerjanja zdravila, razporeditve obrokov ali telesne aktivnosti.
EXUBERA is a fast-acting insulin. 
Zdravilo EXUBERA je hitrodelujoč insulin.
Also contains: Mannitol, glycine, sodium citrate (as dihydrate), sodium hydroxide 
Vsebuje tudi: manitol, glicin, natrijev citrat (v obliki dihidrata), natrijev hidroksid.
Push the base 
Potisnite podnožje
Some patients have experienced fluid in the lung lining (pleural effusion). 
Pri nekaterih bolnikih se je pojavila tekočina v pljučih (plevralni izliv).
REPLACING YOUR INHALER AND THE INSULIN RELEASE (IRU) 
ZAMENJAVA INHALATORJA IN NASTAVKA ZA SPROŠČANJE INSULINA (IRU)
In most of these studies the percentages of patients achieving HbA1c < 7.0% were higher for patients using a regimen including EXUBERA compared to patients on oral agents alone. 
V večini od teh študij so bili odstotni deleži bolnikov, ki so dosegli HbA1c < 7,0 %, višji pri bolnikih, ki so uporabljali shemo, ki je vključevala zdravilo EXUBERA, kot pri bolnikih, zdravljenih samo s peroralnimi antidiabetiki.
EXUBERA is available in 1 mg and 3 mg unit dose blisters which are for administration via the lungs by oral inhalation only with the insulin inhaler. 
EXUBERA je na voljo v 1-mg in 3-mg enoodmernih pretisnih omotih, ki so namenjeni samo uporabi skozi pljuča s peroralnim inhaliranjem z insulinskim inhalatorjem.
Exubera (6mg) Fast-acting Human Insulin (18 U) 
SC Lispro (18 i.e.) Exubera (6 mg) hitrodelujoči humani insulin (18 i.e.)
Substances that may reduce the blood-glucose lowering effect include corticosteroids, danazol, oral contraceptives, thyroid hormones, growth hormone, sympathomimetic agents and thiazides. 
Snovi, ki lahko zmanjšajo hipoglikemični učinek, vključujejo kortikosteroide, danazol, peroralne kontraceptive, ščitnične hormone, rastni hormon, simpatomimetike in tiazide.
Octreotide/lanreotide may both decrease or increase insulin requirements. 
Oktreotid/lanreotid lahko potrebe po insulinu bodisi zmanjša bodisi zveča.
Bronchospasm may rarely occur. 
Le redko se utegne pojaviti bronhospazem.
Quickly form a seal with your lips around the mouthpiece so the insulin will not leak out. 
Hitro vtaknite ustnik v usta in našobite ustnice okrog njega, da insulin ne bo uhajal med ustnicami in ustnikom.
Dampen a clean soft cloth and use mild liquid soap to wipe the outside and inside of the chamber and mouthpiece. 
Ovlažite suho mehko krpo z blagim tekočim detergentom in z njo od zunaj in od znotraj obrišite komoro in ustnik.
You should change the IRU in your insulin inhaler every 2 weeks. 
Nastavek za sproščanje insulina (IRU) v insulinskem inhalatorju zamenjajte vsaka 2 tedna.
Do not use EXUBERA after the expiry date (EXP) stated on the pack or unit dose blisters. 
Zdravila EXUBERA ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatlici (EXP) ali enoodmernih pretisnih omotih (EXP).
EXUBERA is not recommended for patients with lung disease. 
Zdravila EXUBERA ne priporočamo bolnikom s pljučnimi boleznimi.
Where pulmonary oedema is present, or there is a clinically relevant reduction in pulmonary function, EXUBERA should be discontinued and the patient switched to injectable insulin. 
V primeru pljučnega edema ali klinično pomembnega zmanjšanja delovanja pljuč je treba zdravljenje z EXUBERO prekiniti in bolnika prevesti na insulin za injiciranje.